Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder

Journal of Medical Economics

Volumn 18, Issue 11, 2015, Pages 919-929

  Zhou, Zheng Yi ^a   Sun, Shawn ^b   Chopra, Pooja ^a   Zhong, Yichen ^a   Totev, Todor ^a   Signorovitch, James ^a  

^a ANALYSIS GROUP   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Costs and cost analysis; Healthcare resource utilization; Major depressive disorder; Selective serotonin re uptake inhibitors; Vilazodone

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VILAZODONE; ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; EMERGENCY WARD; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAL SERVICE; OUTPATIENT; PRESCRIPTION; AMBULATORY CARE; COST; DEPRESSIVE DISORDER, MAJOR; ECONOMICS; EMERGENCY HEALTH SERVICE; HEALTH SERVICE; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; UTILIZATION;

ADULT; AMBULATORY CARE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; COSTS AND COST ANALYSIS; DEPRESSIVE DISORDER, MAJOR; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEALTH SERVICES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; VILAZODONE HYDROCHLORIDE;

EID: 84945122522     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2015.1061534     Document Type: Article

References (74)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCSR). JAMA 2003;289:3095-105
2. Hasin DS, Goodwin RD, Stinson FS, et al. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 2005;62:1097-106
3. US Burden of Disease Collaborators. The State of US Health, 1990-2010: Burden of Diseases, Injuries, and Risk Factors. JAMA 2013;310:591-606 doi:10.1001/jama.2013.13805
4. Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013;382:1575-86
5. Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med 2013;10:e1001547
6. Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007;370:851-8
7. Greenberg PE, Fournier A-A, Sisitsky T, et al. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry 2015;76:155-62
8. Ivanova JI, Birnbaum HG, Kidolezi Y, et al. Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder. Curr Med Res Opin 2010;26:2475-84
9. IsHak WW, Mirocha J, Pi S, et al. Patient-reported outcomes before and after treatment of major depressive disorder. Dialogues Clin Neurosci 2014;16:171-83
10. Mrazek DA, Biernacka JM, McAlpine DE, et al. Treatment outcomes of depression: the pharmacogenomic research network antidepressant medication pharmacogenomic study. J Clin Psychopharmacol 2014;34:313-17
11. IsHak WW, Greenberg JM, Balayan K, et al. Quality of life: the ultimate outcome measure of interventions in major depressive disorder. Harv Rev Psychiatry 2011;19:229-39
12. Woo J-M, Kim W, Hwang T-Y, et al. Impact of depression on work productivity and its improvement after outpatient treatment with antidepressants. Value Health 2011;14:475-82
13. Tournier M, Crott R, Gaudron Y, et al. Economic impact of antidepressant treatment duration in naturalistic conditions. Acta Psychiatr Scand 2013;127:365-72
14. Pan Y-J, Knapp M, McCrone P. Impact of initial treatment outcome on longterm costs of depression: a 3-year nationwide follow-up study in Taiwan. Psychol Med 2014;44:1147-58
15. Davidson JRT. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry 2010;71(E Suppl):e04
16. Nutt DJ, Davidson JRT, Gelenberg AJ, et al. International consensus statement on major depressive disorder. J Clin Psychiatry 2010;71(E Suppl):e08
17. Uchida N, Chong M-Y, Tan CH, et al. International study on antidepressant prescription pattern at 20 teaching hospitals and major psychiatric institutions in East Asia: analysis of 1898 cases from China, Japan, Korea, Singapore and Taiwan. Psychiatry Clin Neurosci 2007;61:522-8
18. Exeter D, Robinson E, Wheeler A. Antidepressant dispensing trends in New Zealand between 2004 and 2007. Aust N Z J Psychiatry 2009;43: 1131-40
19. Bauer M, Monz BU, Montejo AL, et al. Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study. Eur Psychiatry 2008;23:66-73
20. Ornstein S, Stuart G, Jenkins R. Depression diagnoses and antidepressant use in primary care practices: a study from the Practice Partner Research Network (PPRNet). J Fam Pract 2000;49:68-72
21. Lin H-C, Erickson SR, Balkrishnan R. Physician prescribing patterns of innovative antidepressants in the United States: the case of MDD patients 1993-2007. Int J Psychiatry Med 2011;42:353-68
22. Schatzberg AF. Safety and tolerability of antidepressants: weighing the impact on treatment decisions. J Clin Psychiatry 2007;68(8 Suppl):26-34
23. Anderson IM. Meta-analytical studies on new antidepressants. Br Med Bull 2001;57:161-78
24. Koenig AM, Thase ME. First-line pharmacotherapies for depression - what is the best choice? Pol Arch Med Wewne{ogonek} trznej 2009;119:478-86
25. Valuck R. Selective serotonin reuptake inhibitors: a class review. Pharm Ther 2004;29:234-43
26. Warden D, Rush AJ, Trivedi MH, et al. The STAR∗D project results: a comprehensive review of findings. Curr Psychiatry Rep 2007;9:449-59
27. Huynh NN, McIntyre RS. What are the implications of the STAR∗D trial for primary care? A review and synthesis. Prim Care Companion J Clin Psychiatry 2008;10:91-6
28. Thase ME, Nierenberg AA, Vrijland P, et al. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol 2010;25:189-98
29. Machado M, Einarson TR. Comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials. J Clin Pharm Ther 2010;35:177-88
30. Thase M, Connolly KR. Unipolar depression in adults: treatment of resistant depression. In: Roy-Byrne PP, ed. Waltham, MA: Wolters Kluwer Health; 2015. Available at: http://www.uptodate.com/contents/unipolar-depressionin-adults-treatment-of-resistant-depression. Accessed May 19, 2015
31. Taylor D, Lenox-Smith A, Bradley A. A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose. Ther Adv Psychopharmacol 2013;3:151-61
32. Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry 2008;63:699-704
33. Lam RW, Lönn SL, Despiégel N. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis. Int Clin Psychopharmacol 2010;25: 199-203
34. Signorovitch J, Ramakrishnan K, Ben-Hamadi R, et al. Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors. Curr Med Res Opin 2011;27:1089-96
35. Santaguida P (Lina), MacQueen G, Keshavarz H, et al. Treatment for depression after unsatisfactory response to SSRIs. Comparative Effectiveness Reviews, No. 62. McMaster University Evidence-based Practice Center Report No.: 12-EHC050-EF. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Apr. http://www.ncbi.nlm.nih.gov/books/PMH0046379/. Accessed May 19, 2015
36. Millan MJ. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006;110:135-370
37. Connolly KR, Thase ME. Emerging drugs for major depressive disorder. Expert Opin Emerg Drugs 2012;17:105-26
38. Forest Labs Inc. Vilazodone. Silver Spring, MD: U.S. Food and Drug Administration, 2011. http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2011/022567s000ltr.pdf. Accessed November 8, 2014
39. Watson JM, Dawson LA. Characterization of the potent 5-HT(1A/B) receptor antagonist and serotonin reuptake inhibitor SB-649915: preclinical evidence for hastened onset of antidepressant/anxiolytic efficacy. CNS Drug Rev 2007;13:206-23
40. Hughes ZA, Starr KR, Langmead CJ, et al. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol 2005;510:49-57
41. Ashby CR, Kehne JH, Bartoszyk GD, et al. Electrophysiological evidence for rapid 5-HT1A autoreceptor inhibition by vilazodone, a 5-HT1A receptor partial agonist and 5-HT reuptake inhibitor. Eur J Pharmacol 2013;714:359-65
42. Robinson DS, Kajdasz DK, Gallipoli S, et al. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. J Clin Psychopharmacol 2011;31:643-6
43. Pierz KA, Thase ME. A review of vilazodone, serotonin, and major depressive disorder. Prim Care Companion CNS Disord 2014;16:e1-e8
44. Jain R, Chen D, Edwards J, et al. Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials. Curr Med Res Opin 2014;30:263-70
45. Clayton AH, Kennedy SH, Edwards JB, et al. The effect of vilazodone on sexual function during the treatment of major depressive disorder. J Sex Med 2013;10:2465-76
46. Rickels K, Athanasiou M, Robinson DS, et al. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:326-33
47. Khan A, Sambunaris A, Edwards J, et al. Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression. Int Clin Psychopharmacol 2014;29:86-92
48. Mathews M, Gommoll C, Chen D, et al. Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 2015;30:67-74
49. Citrome L, Gommoll CP, Tang X, et al. Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder: post-hoc analyses of a phase IV trial. Int Clin Psychopharmacol 2015;30:75-81
50. Croft HA, Pomara N, Gommoll C, et al. Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2014;75:e1291-8
51. Wang S-M, Han C, Lee S-J, et al. A review of current evidence for vilazodone in major depressive disorder. Int J Psychiatry Clin Pract 2013;17:160-9
52. Citrome L. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2012;66:356-68
53. Dawson LA. The discovery and development of vilazodone for the treatment of depression: a novel antidepressant or simply another SSRI? Expert Opin Drug Discov 2013;8:1529-39
54. Deardorff WJ, Grossberg GT. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Expert Opin Pharmacother 2014;15:2525-42
55. U.S. Bureau of Labor Statistics. Consumer Price Index-All Urban Consumers: U.S. Medical Care, 1982-84. Washington, DC: U.S. Bureau of Labor Statistics, 2014. http://data.bls.gov/cgi-bin/surveymost. Accessed November 26, 2014
56. Wu EQ, Greenberg PE, Ben-Hamadi R, et al. Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram. Am Heal Drug Benefits 2011;4:78-87
57. Wade AG, Toumi I, Hemels MEH. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr Med Res Opin 2005;21:631-42
58. Wade AG, Toumi I, Hemels MEH. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom. Clin Ther 2005;27:486-96
59. Hemels MEH, Kasper S, Walter E, et al. Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression. Ann Pharmacother 2004;38:954-60
60. Sørensen J, Stage KB, Damsbo N, et al. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care. Nord J Psychiatry 2007;61:100-8
61. Demyttenaere K, Hemels MEH, Hudry J, et al. A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin Ther 2005;27:111-24
62. Lançon C, Verpillat P, Annemans L, et al. Escitalopram in major depressive disorder: clinical benefits and cost effectiveness versus citalopram. Int J Psychiatry Clin Pract 2007;11:44-52
63. Trkulja V. Is escitalopram really relevantly superior to citalopram in treatment of major depressive disorder? A meta-analysis of head-to-head randomized trials. Croat Med J 2010;51:61-73
64. Svensson S, Mansfield PR. Escitalopram: superior to citalopram or a chiral chimera? Psychother Psychosom 2004;73:10-16
65. Cantrell CR, Eaddy MT, Shah MB, et al. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care 2006;44:300-3
66. Sansone RA, Sansone LA. Antidepressant adherence: are patients taking their medications? Innov Clin Neurosci 2012;9:41-6
67. Sawada N, Uchida H, Suzuki T, et al. Persistence and compliance to antidepressant treatment in patients with depression: a chart review. BMC Psychiatry 2009;9:38
68. Aljumah K, Ahmad Hassali A, AlQhatani S. Examining the relationship between adherence and satisfaction with antidepressant treatment. Neuropsychiatr Dis Treat 2014;10:1433-8
69. Hunot VM, Horne R, Leese MN, et al. A cohort study of adherence to antidepressants in primary care: the influence of antidepressant concerns and treatment preferences. Prim Care Companion J Clin Psychiatry 2007; 9:91-9
70. Wu E, Greenberg PE, Yang E, et al. Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population. Curr Med Res Opin 2008;24:2587-95
71. Wu EQ, Yu AP, Lauzon V, et al. Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder. Ann Pharmacother 2011;45:441-51
72. Garnick DW, Hendricks AM, Comstock CB. Measuring quality of care: fundamental information from administrative datasets. Int J Qual Heal Care 1994;6:163-77
73. Motheral BR, Fairman KA. The use of claims databases for outcomes research: rationale, challenges, and strategies. Clin Ther 1997;19:346-66
74. Melfi CA, Croghan TW. Use of claims data for research on treatment and outcomes of depression care. Med Care 1999;37:AS77-80